These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 15454391

  • 1. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells.
    Cilenti L, Kyriazis GA, Soundarapandian MM, Stratico V, Yerkes A, Park KM, Sheridan AM, Alnemri ES, Bonventre JV, Zervos AS.
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F371-9. PubMed ID: 15454391
    [Abstract] [Full Text] [Related]

  • 2. The serine protease Omi/HtrA2 is involved in XIAP cleavage and in neuronal cell death following focal cerebral ischemia/reperfusion.
    Althaus J, Siegelin MD, Dehghani F, Cilenti L, Zervos AS, Rami A.
    Neurochem Int; 2007 Jan; 50(1):172-80. PubMed ID: 16978742
    [Abstract] [Full Text] [Related]

  • 3. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion.
    Liu HR, Gao E, Hu A, Tao L, Qu Y, Most P, Koch WJ, Christopher TA, Lopez BL, Alnemri ES, Zervos AS, Ma XL.
    Circulation; 2005 Jan 04; 111(1):90-6. PubMed ID: 15611365
    [Abstract] [Full Text] [Related]

  • 4. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D.
    Gynecol Oncol; 2005 May 04; 97(2):413-21. PubMed ID: 15863139
    [Abstract] [Full Text] [Related]

  • 5. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways.
    Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R.
    Cell Death Differ; 2004 Feb 04; 11(2):208-16. PubMed ID: 14605674
    [Abstract] [Full Text] [Related]

  • 6. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity.
    van Loo G, van Gurp M, Depuydt B, Srinivasula SM, Rodriguez I, Alnemri ES, Gevaert K, Vandekerckhove J, Declercq W, Vandenabeele P.
    Cell Death Differ; 2002 Jan 04; 9(1):20-6. PubMed ID: 11803371
    [Abstract] [Full Text] [Related]

  • 7. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells.
    Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL.
    Am J Physiol Renal Physiol; 2004 Sep 04; 287(3):F543-9. PubMed ID: 15149969
    [Abstract] [Full Text] [Related]

  • 8. Cilastatin attenuates cisplatin-induced proximal tubular cell damage.
    Camano S, Lazaro A, Moreno-Gordaliza E, Torres AM, de Lucas C, Humanes B, Lazaro JA, Milagros Gomez-Gomez M, Bosca L, Tejedor A.
    J Pharmacol Exp Ther; 2010 Aug 04; 334(2):419-29. PubMed ID: 20435919
    [Abstract] [Full Text] [Related]

  • 9. The mitochondrial serine protease HtrA2/Omi cleaves RIP1 during apoptosis of Ba/F3 cells induced by growth factor withdrawal.
    Vande Walle L, Wirawan E, Lamkanfi M, Festjens N, Verspurten J, Saelens X, Vanden Berghe T, Vandenabeele P.
    Cell Res; 2010 Apr 04; 20(4):421-33. PubMed ID: 20125124
    [Abstract] [Full Text] [Related]

  • 10. Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells.
    Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J.
    J Chemother; 2008 Jun 04; 20(3):348-54. PubMed ID: 18606591
    [Abstract] [Full Text] [Related]

  • 11. Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation.
    Kuninaka S, Iida SI, Hara T, Nomura M, Naoe H, Morisaki T, Nitta M, Arima Y, Mimori T, Yonehara S, Saya H.
    Oncogene; 2007 Apr 12; 26(17):2395-406. PubMed ID: 17130845
    [Abstract] [Full Text] [Related]

  • 12. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G.
    Li S, Basnakian A, Bhatt R, Megyesi J, Gokden N, Shah SV, Portilla D.
    Am J Physiol Renal Physiol; 2004 Nov 12; 287(5):F990-8. PubMed ID: 15280156
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
    Hu XY, Xu YM, Chen XC, Ping H, Chen ZH, Zeng FQ.
    APMIS; 2006 Dec 12; 114(12):893-8. PubMed ID: 17207090
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Omi/HtrA2 Regulates a Mitochondria-Dependent Apoptotic Pathway in a Murine Model of Septic Encephalopathy.
    Wang P, Hu Y, Yao D, Li Y.
    Cell Physiol Biochem; 2018 Dec 12; 49(6):2163-2173. PubMed ID: 30286467
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Specific protein interaction of human Pag with Omi/HtrA2 and the activation of the protease activity of Omi/HtrA2.
    Hong SK, Cha MK, Kim IH.
    Free Radic Biol Med; 2006 Jan 15; 40(2):275-84. PubMed ID: 16413409
    [Abstract] [Full Text] [Related]

  • 19. Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury.
    Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V.
    Peptides; 2010 Apr 15; 31(4):592-602. PubMed ID: 20034524
    [Abstract] [Full Text] [Related]

  • 20. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X, Fraser M, Moll UM, Basak A, Tsang BK.
    Cancer Res; 2006 Mar 15; 66(6):3126-36. PubMed ID: 16540663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.